Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 145Stomach Neoplasms 22Triple Negative Breast Neoplasms 21Inflammatory Breast Neoplasms 14Carcinoma, Hepatocellular 13Esophageal Neoplasms 11Lymphoma, Large B-Cell, Diffuse 7Neoplasms 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Adenocarcinoma Of Esophagus 4Testicular Neoplasms 3Sarcoma 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Non-Muscle Invasive Bladder Neoplasms 3Liver Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Pathologic Complete Response 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2HER2-negative Breast Cancer 2Carcinoma, Adenoid Cystic 2Breast Diseases 2pCR Rate 1Women With Primary Breast Cancer 1

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Epirubicin × Clear all
NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡